What is the preferred drug for PDA?

Preferred Medications for Treating Patent Ductus Arteriosus in Neonates

Patent ductus arteriosus (PDA) is a common condition in premature infants, where the ductus arteriosus—a blood vessel connecting the pulmonary artery and aorta—fails to close after birth. If left untreated, it can lead to complications such as heart failure, respiratory distress, and poor weight gain. Prompt medical intervention is often necessary, especially in preterm newborns.

Indomethacin and ibuprofen are the two primary medications used to treat PDA, both belonging to the class of nonsteroidal anti-inflammatory drugs (NSAIDs) that inhibit prostaglandin synthesis. Since prostaglandins help keep the ductus arteriosus open during fetal life, blocking their action encourages closure after birth.

Indomethacin has been used for decades and is particularly effective in the first few days of life. It is often preferred in very low birth weight infants and in settings where early closure is critical. However, concerns about its potential impact on cerebral and renal blood flow have led some clinicians to favor ibuprofen, which appears to have a more favorable safety profile with fewer effects on organ perfusion.

Ibuprofen, though slightly newer in this context, has gained widespread acceptance as an equally effective alternative with comparable success rates in closing the ductus. Studies suggest it may carry a lower risk of transient kidney dysfunction and reduced blood flow to vital organs.

While both drugs are effective, the choice between indomethacin and ibuprofen often depends on the infant’s clinical condition, gestational age, and institutional protocols. In some cases, when pharmacological treatment fails, surgical ligation may be considered.

Ultimately, the management of PDA requires careful evaluation by a neonatal care team. With timely intervention using these prostaglandin inhibitors, many infants achieve successful closure without long-term complications.